SCHEMBL14448917

SCHEMBL14448917

O=C1Nc2ccc(Cl)cc2/C1=C/c1c[nH]c2ccccc12

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 6/20 0.73
NTRK1 P04629 5/20 0.73
RET P07949 3/20 0.73
PDGFRB P09619 3/20 0.73
PRKD3 O94806 2/20 0.73
ABL1 P00519 2/20 0.73
LTK P29376 2/20 0.73
KDR P35968 2/20 0.73
FLT3 P36888 2/20 0.73
CSNK1A1 P48729 2/20 0.73
CDK7 P50613 2/20 0.73
MAP2K1 Q02750 2/20 0.73
MST1R Q04912 2/20 0.73
NTRK3 Q16288 2/20 0.73
NTRK2 Q16620 2/20 0.73
AURKB Q96GD4 2/20 0.73
CLK4 Q9HAZ1 2/20 0.73
ALK Q9UM73 2/20 0.73
RPS6KA3 P51812 2/20 0.73
DAPK3 O43293 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5464550 1.00 LRRK2 (0.73) LRRK2NTRK1RETPDGFRBPRKD3
SCHEMBL5464546 1.00 LRRK2 (0.73) LRRK2NTRK1RETPDGFRBPRKD3
SCHEMBL5469553 0.90 NTRK1 (0.73) LRRK2NTRK1RETPDGFRBPRKD3
SCHEMBL14448948 0.90 NTRK1 (0.73) LRRK2NTRK1RETPDGFRBPRKD3
SCHEMBL5469550 0.90 NTRK1 (0.73) LRRK2NTRK1RETPDGFRBPRKD3
SCHEMBL14448924 0.85 NTRK1 (0.73) LRRK2NTRK1RETPDGFRBPRKD3
SCHEMBL5472580 0.85 NTRK1 (0.73) LRRK2NTRK1RETPDGFRBPRKD3
SCHEMBL14448928 0.85 NTRK1 (0.73) LRRK2NTRK1RETPDGFRBPRKD3
SCHEMBL5472578 0.85 NTRK1 (0.73) LRRK2NTRK1RETPDGFRBPRKD3
SCHEMBL5470630 0.85 NTRK1 (0.73) LRRK2NTRK1RETPDGFRBPRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US disclosed
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167488-A1 Novel therapeutic use MAG, PMP22, MYT1 LRRK2 1753/4885NTRK1 175/4885RET 3720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.